EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Duration of Therapy for Pseudomonas aeruginosa Bacteremia—A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial

Dafna Yahav iD, Ruxandra Pinto iD, Deborah Cook, Joshua Davis, Erick Duan, Tomer Hoffman iD, Todd C Lee iD, Emily G McDonald, Susan Morpeth, John Muscedere iD, Wendy Sligl, Terence Wuerz iD und 3 weitere

Clinical Infectious Diseases · 23.07.2026 · 83 (1) · 41-47

DOI: 10.1093/cid/ciag144 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.03.2026. Verfasst von Dafna Yahav und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel. Hauptthemen laut MEDLINE: Bacteremia, Pseudomonas Infections, Anti-Bacterial Agents, Pseudomonas aeruginosa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the clinical significance of Pseudomonas aeruginosa bacteremia, the optimal duration of antibiotic therapy is unclear. We aimed to explore the association of antibiotic duration on mortality in hospitalized patients with P aeruginosa bacteremia.

Methods

This study was a post hoc analysis of all patients with P aeruginosa bacteremia included in the Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomized controlled trial comparing 7 versus 14 days of antibiotic therapy for bacteremia. The primary outcome was 90-day mortality. Unadjusted risk differences (RDs) with 95% CIs for outcomes were calculated for patients randomized to 7 versus 14 days of treatment. Multivariable logistic regression was used to evaluate independent predictors of mortality.

Results

Among 157 patients with P aeruginosa bacteremia, 74 were randomized to 7 days of antibiotic treatment and 83 to 14 days. Patients in the 7-day group were more likely to be men and acquire infection in hospital. Crude mortality at 90 days in the intention-to-treat population was 22/74 (29.7%) in the 7-day group versus 17/83 (20.5%) in the 14-day group (RD: 9.2; 95% CI: −4.8 to 23.2). Age was associated with 90-day mortality (odds ratio [OR]: 1.06; 95% CI: 1.02–1.09), but randomization group (7 or 14 days) was not (OR: 1.47; 95% CI: .66–3.27).

Conclusions

Among patients with P aeruginosa bacteremia included in an international trial testing duration of antibiotic treatment, no significant difference in mortality was demonstrated between 7 versus 14 days of antibiotic therapy; however, a limited sample size precludes a conclusion of noninferiority, benefit, or harm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaPseudomonas InfectionsAnti-Bacterial AgentsPseudomonas aeruginosaDuration of TherapyHumansMaleFemaleMiddle AgedAgedTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

Pseudomonas aeruginosa bacteremiaBALANCE trialantibiotic therapydurationmortality

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
  • Faculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
  • Department of Critical Care Medicine, Sunnybrook Health Sciences Centre; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
  • Division of Critical Care, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Dafna Yahav, Ruxandra Pinto, Tomer Hoffman, Todd C Lee, John Muscedere, Terence Wuerz

Zitieren

APA

Yahav, D., Pinto, R., Cook, D., Davis, J., Duan, E., Hoffman, T., Lee, T. C., McDonald, E. G., Morpeth, S., Muscedere, J., Sligl, W., Wuerz, T., Fowler, R. A., Daneman, N., & BALANCE Consortium (2026). Duration of Therapy for Pseudomonas aeruginosa Bacteremia—A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial. Clinical Infectious Diseases, 83(1), 41-47. https://doi.org/10.1093/cid/ciag144

Vancouver

Yahav D, Pinto R, Cook D, Davis J, Duan E, Hoffman T, et al. Duration of Therapy for Pseudomonas aeruginosa Bacteremia—A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial. Clinical Infectious Diseases. 2026;83(1):41-47. doi:10.1093/cid/ciag144

BibTeX
@article{Yahav2026,
  author = {Yahav, Dafna and Pinto, Ruxandra and Cook, Deborah and Davis, Joshua and Duan, Erick and Hoffman, Tomer and Lee, Todd C and McDonald, Emily G and Morpeth, Susan and Muscedere, John and Sligl, Wendy and Wuerz, Terence and Fowler, Robert A and Daneman, Nick and BALANCE Consortium, BALANCE Consortium},
  title = {Duration of Therapy for Pseudomonas aeruginosa Bacteremia—A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {83},
  number = {1},
  pages = {41--47},
  doi = {10.1093/cid/ciag144}
}
Kostenlos starten →